Innovent and Sirnaomics to combine sintilimab and RNAi in cancer

8 January 2020

Chinese biopharma Innovent Biologics (HKEX: 01801) has teamed up with RNAi specialist Sirnaomics to combine their therapies in cancer trials.

The companies have entered a strategic collaboration to conduct clinical studies, using Innovent's antibody drug Tyvyt (sintilimab injection) and Sirnaomics' RNAi drug candidate STP705 (cotsiranib), for combination treatment in advanced cancers, such as hepatocellular carcinomas (HCC).

"This will be the first combination using an RNAi drug candidate together with an approved immune checkpoint antibody drug for the treatment of liver cancers"Sintilimab was granted marketing approval in China in 2018 and has been the only PD-1 inhibitor included in the National Reimbursement Drug List since 2019.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK